At 17.5% CAGR, Middle East & Africa Cell and Gene Therapy Market is Projected to be Worth US$ 469.34 Million by 2031, says Business Market Insights

According to Business Market Insights' research, the Middle East & Africa cell and gene therapy market was valued at US$ 129.17 million in 2023 and is projected to reach US$ 469.34 million by 2031, registering a CAGR of 17.5% from 2023 to 2031. Increase in number of approvals of cell and gene therapies and rapid popularity of outsourcing cell and gene therapy manufacturing are among the critical factors attributed to drive the Middle East & Africa cell and gene therapy market growth.

The advancements in biotechnology have led to the adoption of personalized treatments for a wide range of indications. Stem cell therapies are being used to treat cancer, neurological disorders, genetic disorders, and other chronic diseases. Further, the advantages of cell therapy include targeted treatment, rapid and efficient recovery, and reduced side effects. Cell therapies are widely adopted worldwide owing to the availability of Food and Drug Administration (FDA) approved products. A few of the cell and gene therapy products approved by the FDA in recent years are: In April 2024, the FDA approved BEQVEZ for use by Pfizer Inc. to treat adults suffering from moderate to severe hemophilia B who are on factor IX (FIX) prophylaxis therapy. A FIX deficiency causes people with hemophilia B, a rare genetic bleeding illness, to bleed more frequently and for longer periods than healthy people. The disease hinders normal blood clotting. In 2023, the FDA approved VYJUVEK, manufactured by Krystal Biotech, Inc., for the treatment of wounds in patients ages 6 months and above with dystrophic epidermolysis bullosa, showing mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene. In 2022, ADSTILADRIN, an adenovirus manufactured by Ferring Pharmaceuticals A/S, was approved by the FDA. This recombinant adenovirus (rAd-IFNa/Syn3) delivers human interferon alfa-2b cDNA into the bladder epithelium to treat patients with certain types of bladder cancer. In 2022, CARVYKTI, manufactured by Janssen Biotech, Inc.-an autologous CAR-T cell engineered with lentivirus to attack BCMA-expressing tumor cells for the treatment of certain kinds of relapsed or refractory multiple myeloma-was also approved by the FDA. In 2022, the FDA approved HEMGENIX, manufactured by CSL Behring LLC, which is a recombinant AAV5 that delivers F9 to treat patients with certain kinds of Hemophilia B. In March 2021, the first anti-BCMA CAR T cell therapy for relapsed or resistant multiple myeloma, called Abecma (idecabtagene vicleucel), has been approved by the US FDA for use by Bristol Myers Squibb and Bluebird Bio. In April 2020, the FDA awarded regenerative medicine advanced therapy designation to Novartis' Kymriah to treat refractory (r/r) follicular lymphoma (FL) in adults. In July 2020, the FDA approved a CAR T-cell therapy brexucabtagene autoleucel (Tecartus) for patients with mantle cell lymphoma. It is the first FDA-approved CAR T-cell therapy for mantle cell lymphoma, and it was approved under the accelerated approval pathway. Tecartus also received Orphan Drug designation, which encourages the development of drugs for rare diseases. The other approved CAR-T cell therapies for cancer are Kymriah for acute lymphoblastic leukemia and Yescarta for diffuse large B-cell lymphoma. Therefore, the increasing number of approvals of cell and gene therapies enhances manufacturing capabilities, which fuels the Asia Pacific cell and gene therapy market growth.

On the contrary, high cost of cell and gene therapy manufacturing hampers the growth of Middle East & Africa cell and gene therapy market.

Based on type, the Middle East & Africa cell and gene therapy market is bifurcated into cell therapy and gene therapy. The cell therapy segment held 69.7% market share in 2023, amassing US$ 90.01 million. It is projected to garner US$ 369.32 million by 2031 to register 19.3% CAGR during 2023-2031. Furthermore, the cell therapy segment is subcategorized into allogeneic, autologous, viral vectors. Additionally, the gene therapy segment is bifurcated into non-viral vectors and viral vectors.

In terms of services, the Middle East & Africa cell and gene therapy market is segmented into process development, cGMP manufacturing, regulatory services, and bioassay services. The process development segment held 42.5% share of Middle East & Africa cell and gene therapy market in 2023, amassing US$ 54.86 million. It is anticipated to garner US$ 220.76 million by 2031 to expand at 19.0% CAGR during 2023-2031.

By scale, the Middle East & Africa cell and gene therapy market is divided into pre-commercial/ R and D manufacturing and commercial scale manufacturing. The pre-commercial/ R and D manufacturing segment held 71.4% share of Middle East & Africa cell and gene therapy market in 2023, amassing US$ 92.28 million. It is projected to garner US$ 344.76 million by 2031 to expand at 17.9% CAGR from 2023 to 2031.

By end user, the Middle East & Africa cell and gene therapy market is segmented into contract research organizations, pharmaceutical and biopharmaceutical companies, and academic and research institutes. The pharmaceutical and biopharmaceutical companies segment held 51.2% share of Middle East & Africa cell and gene therapy market in 2023, amassing US$ 66.16 million. It is estimated to garner US$ 223.10 million by 2031 to expand at 16.4% CAGR during 2023-2031.

Based on country, the Middle East & Africa cell and gene therapy market is categorized into South Africa, Saudi Arabia, the U.A.E, and the Rest of Middle East & Africa. Our regional analysis states that South Africa captured 38.6% share of Middle East & Africa cell and gene therapy market in 2023. It was assessed at US$ 49.80 million in 2023 and is likely to hit US$ 207.29 million by 2031, registering a CAGR of 19.5% during 2023-2031.

Key players operating in the Middle East & Africa cell and gene therapy market are Catalent Inc., Charles River Laboratories International Inc, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corp, Lonza Group AG, Lotte Corp, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc., and WuXi AppTec Co Ltd, among others.

- In February 2024, Novo Holdings has entered an agreement to acquire Catalent, Inc. under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com